News
ADPT
13.53
-3.63%
-0.51
Weekly Report: what happened at ADPT last week (0420-0424)?
Weekly Report · 2d ago
Adaptive Biotechnologies President, COO Julie Rubinstein disposes of shares worth $802,123.4
PUBT · 4d ago
Assessing Adaptive Biotechnologies (ADPT) Valuation After Recent Share Price Weakness
Simply Wall St · 5d ago
Thermo Fisher ranks sixth by Quant as stock falls on Q1 results
Seeking Alpha · 6d ago
Adaptive Biotechnologies President, COO Julie Rubinstein sells $994,273 common shares
PUBT · 04/21 22:08
Adaptive Biotechnologies: Strong Sequencing, Weak Margin Of Safety
Seeking Alpha · 04/20 15:06
Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It Means
The Motley Fool · 04/20 13:12
Weekly Report: what happened at ADPT last week (0413-0417)?
Weekly Report · 04/20 09:09
Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?
The Motley Fool · 04/18 14:57
Adaptive Biotechnologies President, COO Julie Rubinstein disposes of $832,436 common shares
PUBT · 04/16 23:36
Adaptive Biotechnologies sets first-quarter earnings report, conference call webcast
PUBT · 04/15 20:08
U.S. RESEARCH ROUNDUP-Biogen, Equinix, Revolution Medicines
Reuters · 04/14 07:45
Adaptive Biotechnologies President and COO Julie Rubinstein sells USD 526,477 shares
PUBT · 04/13 23:45
Weekly Report: what happened at ADPT last week (0406-0410)?
Weekly Report · 04/13 09:09
Adaptive Biotechnologies Chief People Officer Francis Lo sells $340,043 common shares
Reuters · 04/10 22:53
Adaptive Biotech CSO Harlan Robins sells 10,000 shares worth $148,500
Reuters · 04/10 22:49
Mid-cap healthcare stocks with A grade EPS revisions ahead of earnings
Seeking Alpha · 04/10 21:14
Adaptive Biotechnologies CEO Chad Robins disposes of USD 1.8 million common shares
Reuters · 04/08 23:51
Adaptive Biotechnologies President, COO Julie Rubinstein disposes of USD 983,470 shares
Reuters · 04/08 23:49
Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus On
The Motley Fool · 04/08 13:33
More
Webull provides a variety of real-time ADPT stock news. You can receive the latest news about Adaptive Biotechnologies through multiple platforms. This information may help you make smarter investment decisions.
About ADPT
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform reveals and translates the massive genetics of the adaptive immune system with scale, precision and speed. It applies its platform to partner with biopharmaceutical companies, inform drug development, and develop clinical diagnostics across its two business segments: Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic test, offered to clinicians. The IM business focuses on the discovery and development of transformative immune-based therapies in the treatment of patients with cancer and autoimmune diseases.